Rise of India's Pharmaceutical Industry in Global Trade
This paper traces the growth of India's pharmaceutical industry from a producer of counterfeit drugs into one of the world's leading exporters of generic medicines. It examines how a 2005 World Trade Organization compliance agreement transformed the industry, attracting foreign partnerships and driving export growth. The paper analyzes the benefits and drawbacks of this rise for U.S. pharmaceutical companies and consumers, including lower costs, improved drug access, and job losses in Western markets. It concludes by applying the Product Life-Cycle Theory and the Heckscher-Ohlin Theory to explain how India's factor endowments — particularly low-cost labor — underpin its comparative advantage in pharmaceutical manufacturing.
- Introduction: Overview of India's pharmaceutical rise and global impact
- Background of the Issue: History from counterfeit drugs to 2005 WTO compliance
- Benefits to U.S. Pharmaceutical Companies and Consumers: Cost, access, and quality gains for American stakeholders
- Disadvantages of the Rise of the Indian Pharmaceutical Industry: Innovation decline and job losses in Western markets
- Benefits vs. Losses: Weighing net trade outcomes for foreign and domestic firms
- International Trade Theory and India's Pharmaceutical Growth: Product Life-Cycle and Heckscher-Ohlin theories applied
- Conclusion: Summary of growth drivers, benefits, and trade theories
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Presents a balanced analysis by examining both the benefits and drawbacks of India's pharmaceutical growth for multiple stakeholders — U.S. companies, U.S. consumers, Indian domestic markets, and Western employment.
- Grounds its claims in concrete data, such as the growth from $429 million to $589 million in drug exports to the U.S. between 2003 and 2005, and the 15% annual export growth rate from 2006 to 2012.
- Connects an industry case study to formal international trade theory, demonstrating the ability to apply academic frameworks (Product Life-Cycle and Heckscher-Ohlin) to real-world phenomena.
Key academic technique demonstrated
The paper demonstrates applied theory analysis — taking established international trade frameworks and mapping their logic directly onto an empirical case. By identifying which theory "best explains" the phenomenon and justifying that claim with evidence, the author shows how to use theory as an interpretive tool rather than merely defining it.
Structure breakdown
The paper opens with an introductory overview, then provides historical background on India's drug sector up to the 2005 WTO turning point. Two central analytical sections assess benefits and disadvantages of the industry's rise, followed by a weighing of net trade outcomes. A dedicated section applies international trade theory before a brief conclusion synthesizes the key findings.
Introduction
The strong growth of India's pharmaceutical industry has been one of the greatest success stories in international trade in recent years. India has traditionally been renowned as a country that produces cheap knockoffs of patented drugs invented or developed by pharmaceutical companies in Japan and the West. As a result, India's drug industry was regarded as an international pariah and a hub for intellectual property rights violations. Moreover, Indian pharmaceutical companies were prohibited from selling their products in developed markets. However, the recent strong growth of this industry is more likely to benefit pharmaceutical companies and consumers in the American drug market as India rises to become a major exporter of pharmaceuticals.
Background of the Issue
India's drug industry relied heavily on supplies from large international corporations until the 1970s, since the domestic sector produced only cheap bulk drugs (Perlitz, Just & Ebling, 2008). State-owned companies founded in the 1950s and 1960s could produce only such drugs, often with the assistance of the World Health Organization. As these companies provided the foundation for the growth of India's drug industry, its development was characterized by several struggles and successes. Over the years, India's pharmaceutical industry was renowned as problematic because it produced cheap knockoffs of patented drugs developed by pharmaceutical companies in Japan and the West. This production of counterfeit goods violated intellectual property rights and marked the industry as an international pariah. Consequently, Indian drug companies were prohibited from selling their products in overseas markets, especially in developed countries. Opportunities for these firms were further limited by the lack of assured intellectual property protection and the refusal of foreign companies to invest in, partner with, or purchase products from their Indian counterparts.
However, India's drug industry took a significant turn in 2005 that has contributed to its status as one of the great success stories in global trade in recent years. Following an agreement with the World Trade Organization that brought the country into compliance with international intellectual property rules, Indian pharmaceutical firms stopped producing counterfeit products. Consequently, foreign companies began partnering with their Indian counterparts, assured that intellectual property rights would be protected. This propelled the dramatic growth of India's drug industry to the point where it generated approximately $30 billion in sales in 2012. That growth was fueled by increasing exports, which rose at 15% per annum between 2006 and 2012. In light of this recent expansion, the sector has become an attractive destination for Western companies seeking to outsource drug manufacturing, as India offers numerous advantages to Western enterprises.
References
Chadha, A. (2007, June). Product cycles, innovation and exports: A study of Indian pharmaceuticals. Retrieved from http://www.webmeets.com/files/papers/EARIE/2007/105/exports_pharma.pdf
Greene, W. (2007, May). The emergence of India's pharmaceutical industry and implications for the U.S. generic drug market. U.S. International Trade Commission. Retrieved from https://www.usitc.gov/publications/332/EC200705A.pdf
Hill, C. W. L. (2015). International business: Competing in the global marketplace (10th ed.). McGraw-Hill.
KPMG International. (2006). The Indian pharmaceutical industry: Collaboration for growth. Retrieved from https://www.in.kpmg.com/pdf/Indian%20Pharma%20Outlook.pdf
Lakshmi, R. (2011, March 11). Foreign takeovers of Indian drug companies fuel fear of rising prices. The Washington Post.
Perlitz, U., Just, T., & Ebling, M. (2008, April 9). India's pharmaceutical industry on course for globalization. Deutsche Bank Research. Retrieved from
Subbu, R. (2014, March 9). U.S. pharma companies benefit from large Indian generic market. The Hindu.
The Economist. (2014, February 20). On closer inspection. The Economist.
Create your account
Always verify citation format against your institution’s current style guide requirements.